Can a vaccine stop shingles from coming back? new study targets adults 50+
NCT ID NCT04091451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-dose shingles vaccine (HZ/su) in 1,430 adults aged 50 and older who had already experienced shingles. The goal was to see if the vaccine could prevent the virus from coming back and to check its safety and immune response. Participants received either the vaccine or a placebo, and researchers tracked new shingles cases over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Barnaul, 656043, Russia
-
GSK Investigational Site
Gatchina, 188300, Russia
-
GSK Investigational Site
Moscow, 115478, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
- Shingles in cancer patients: a hidden cost burden?
- Shingles vaccine protection tested over 6 years in 24,740 adults
- New gel promises shingles pain relief in minutes
- Shingles shot may shield brain: 33,000 seniors test dementia link
- New shingles vaccine trial aims to protect millions over 40